Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Nanotheranostics
|
May 31, 2021
Pentraxin 3: a powerful orchestrator in urinary tract infection
Cheng Qiu, Tianyi Liu, Dan Luo, et al.
Cancer Pathogenesis and Therapy
|
February 8, 2024
Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis
Zhaoxiang Xie, Qianghua Zhou, Cheng Qiu, et al.
Inflammation
|
September 13, 2020
ROS-Dependent Lipid Peroxidation and Reliant Antioxidant Ferroptosis-Suppressor-Protein 1 in Rheumatoid Arthritis: a Covert Clue for Potential Therapy
Zhaoxiang Xie, Haodong Hou, Dan Luo, et al.
Current Problems in Surgery
|
June 13, 2026
Postoperative urinary retention in patients undergoing elective spine surgery
Zhiyuan Xiao, Shiyuan Han, Zhaoxiang Xie, et al.
Biomaterials Science
|
July 14, 2022
Delivery of enzalutamide <i>via</i> nanoparticles for effectively inhibiting prostate cancer progression
Ze Gao, Jun Huang, Zhaoxiang Xie, et al.
ACS Biomaterials Science & Engineering
|
June 8, 2024
Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy
Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
February 16, 2023
Improved in situ sequencing for high-resolution targeted spatial transcriptomic analysis in tissue sections
Xinbin Tang, Jiayu Chen, Xinya Zhang, et al.
Materials Today. Bio
|
January 5, 2026
Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer
Zhaoxiang Xie, Chunlei Dai, Zhi Xiong, et al.
Biomaterials Science
|
January 3, 2024
Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression
Zhi Xiong, Tong Tong, Zhaoxiang Xie, et al.
Cell Death & Disease
|
February 23, 2026
PDHA1-acetylation signaling suppresses cuproptosis to attenuate anti-androgen effect in prostate cancer
Ruilin Zhuang, Qianghua Zhou, Bisheng Cheng, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Nanotheranostics
|
May 31, 2021
Pentraxin 3: a powerful orchestrator in urinary tract infection
Cheng Qiu, Tianyi Liu, Dan Luo, et al.
Cancer Pathogenesis and Therapy
|
February 8, 2024
Inaugurating a novel adjuvant therapy in urological cancers: Ferroptosis
Zhaoxiang Xie, Qianghua Zhou, Cheng Qiu, et al.
Inflammation
|
September 13, 2020
ROS-Dependent Lipid Peroxidation and Reliant Antioxidant Ferroptosis-Suppressor-Protein 1 in Rheumatoid Arthritis: a Covert Clue for Potential Therapy
Zhaoxiang Xie, Haodong Hou, Dan Luo, et al.
Current Problems in Surgery
|
June 13, 2026
Postoperative urinary retention in patients undergoing elective spine surgery
Zhiyuan Xiao, Shiyuan Han, Zhaoxiang Xie, et al.
Biomaterials Science
|
July 14, 2022
Delivery of enzalutamide <i>via</i> nanoparticles for effectively inhibiting prostate cancer progression
Ze Gao, Jun Huang, Zhaoxiang Xie, et al.
ACS Biomaterials Science & Engineering
|
June 8, 2024
Sorafenib Encapsulated Poly(ester amide) Nanoparticles for Efficient and Biosafe Prostate Cancer Therapy
Shunli Yu, Ruhe Zhang, Zhaoxiang Xie, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao
|
February 16, 2023
Improved in situ sequencing for high-resolution targeted spatial transcriptomic analysis in tissue sections
Xinbin Tang, Jiayu Chen, Xinya Zhang, et al.
Materials Today. Bio
|
January 5, 2026
Daidzein-engineered high-accumulation self-therapeutic nanoplatform drives androgen receptor degradation via ubiquitination-proteasome system to overcome enzalutamide resistance in castration-resistant prostate cancer
Zhaoxiang Xie, Chunlei Dai, Zhi Xiong, et al.
Biomaterials Science
|
January 3, 2024
Delivery of gefitinib loaded nanoparticles for effectively inhibiting prostate cancer progression
Zhi Xiong, Tong Tong, Zhaoxiang Xie, et al.
Cell Death & Disease
|
February 23, 2026
PDHA1-acetylation signaling suppresses cuproptosis to attenuate anti-androgen effect in prostate cancer
Ruilin Zhuang, Qianghua Zhou, Bisheng Cheng, et al.
Page
of 2